Abortion and reproductive health care access
Maternal Mental Health
Into the Light for Maternal Mental Health and Substance Use Disorders Act (S. 3824/H.R. 7073)
TRIUMPH for New Moms Act of 2021 (H.R. 4217/S. 2779)
Unwinding of the COVID-19 Public Health Emergency
Initiatives related to inclusion of pregnant and lactating individuals in clinical research
RFI on NIH-Wide Strategic Plan for Research on the Health of Women (Notice Number: NOT-OD-22-186)
Advance Notice of Proposed Rulemaking: Trade Regulation Rule on Commercial Surveillance and Data Security (R111004)
Permanent and mandatory extension of Medicaid for benefits for 12-months post-partum
Graduate medical education
Comments in response to the RFI regarding accessing healthcare and related challenges, understanding provider experiences, advancing health equity, and assessing the impact of waivers and flexibilities provided in response to the COVID-19 Public Health Emergency (PHE)
Issues related to mifepristone
Reproductive Health Services Interim Final Rule, RIN: 2900-AR57
Duration: April 1, 2020
to
November 21, 2022
General Issues: Health Issues , Medicare/Medicaid , Pharmacy , Veterans , Budget/Appropriations , Insurance
Spending: about $376,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2020: U.S. Senate, House of Representatives, Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office, Natl Institutes of Health (NIH), Federal Trade Commission (FTC), Veterans Affairs - Dept of (VA), Health Resources & Services Administration (HRSA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2022
In Q4, ARTEMIS POLICY GROUP LLC lobbied for American College of Obstetricians and Gynecologists , earning $20,000. The report was filed on Jan. 20, 2023.
Original Filing: 301439232.xml
Lobbying Issues
Abortion and reproductive health care access
Maternal Mental Health
Into the Light for Maternal Mental Health and Substance Use Disorders Act (S. 3824/H.R. 7073)
TRIUMPH for New Moms Act of 2021 (H.R. 4217/S. 2779)
Unwinding of the COVID-19 Public Health Emergency
Initiatives related to inclusion of pregnant and lactating individuals in clinical research
RFI on NIH-Wide Strategic Plan for Research on the Health of Women (Notice Number: NOT-OD-22-186)
Advance Notice of Proposed Rulemaking: Trade Regulation Rule on Commercial Surveillance and Data Security (R111004)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) White House Office Natl Institutes of Health (NIH) Federal Trade Commission (FTC)
Lobbying Issues
Permanent and mandatory extension of Medicaid for benefits for 12-months post-partum
Graduate medical education
Comments in response to the RFI regarding accessing healthcare and related challenges, understanding provider experiences, advancing health equity, and assessing the impact of waivers and flexibilities provided in response to the COVID-19 Public Health Emergency (PHE)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to mifepristone
Agencies Lobbied
Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Reproductive Health Services Interim Final Rule, RIN: 2900-AR57
Agencies Lobbied
Veterans Affairs - Dept of (VA)
4th Quarter, 2022
ARTEMIS POLICY GROUP LLC terminated an engagement in which they represented American College of Obstetricians and Gynecologists on Jan. 20, 2023.
Original Filing: 301439346.xml
Lobbying Issues
Abortion and reproductive health care access
Maternal Mental Health
Into the Light for Maternal Mental Health and Substance Use Disorders Act (S. 3824/H.R. 7073)
TRIUMPH for New Moms Act of 2021 (H.R. 4217/S. 2779)
Unwinding of the COVID-19 Public Health Emergency
Initiatives related to inclusion of pregnant and lactating individuals in clinical research
RFI on NIH-Wide Strategic Plan for Research on the Health of Women (Notice Number: NOT-OD-22-186)
Advance Notice of Proposed Rulemaking: Trade Regulation Rule on Commercial Surveillance and Data Security (R111004)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) White House Office Natl Institutes of Health (NIH) Federal Trade Commission (FTC)
Lobbying Issues
Permanent and mandatory extension of Medicaid for benefits for 12-months post-partum
Graduate medical education
Comments in response to the RFI regarding accessing healthcare and related challenges, understanding provider experiences, advancing health equity, and assessing the impact of waivers and flexibilities provided in response to the COVID-19 Public Health Emergency (PHE)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to mifepristone
Agencies Lobbied
Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Reproductive Health Services Interim Final Rule, RIN: 2900-AR57
Agencies Lobbied
Veterans Affairs - Dept of (VA)
3rd Quarter, 2022
In Q3, ARTEMIS POLICY GROUP LLC lobbied for American College of Obstetricians and Gynecologists , earning $10,000. The report was filed on Oct. 19, 2022.
Original Filing: 301410598.xml
Lobbying Issues
Abortion and reproductive health care access
Maternal Mental Health
Into the Light for Maternal Mental Health and Substance Use Disorders Act (S. 3824/H.R. 7073)
TRIUMPH for New Moms Act of 2021 (H.R. 4217/S. 2779)
Unwinding of the COVID-19 Public Health Emergency
Initiatives related to inclusion of pregnant and lactating individuals in clinical research
RFI on NIH-Wide Strategic Plan for Research on the Health of Women (Notice Number: NOT-OD-22-186)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) White House Office Natl Institutes of Health (NIH)
Lobbying Issues
Permanent and mandatory extension of Medicaid for benefits for 12-months post-partum
Graduate medical education
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to mifepristone
Agencies Lobbied
Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Reproductive Health Services Interim Final Rule, RIN: 2900-AR57
Agencies Lobbied
Veterans Affairs - Dept of (VA)
2nd Quarter, 2022
ARTEMIS POLICY GROUP LLC amended a lobbying report for representation of American College of Obstetricians and Gynecologists in Q22022 on Aug. 25, 2022.
Original Filing: 301399419.xml
Lobbying Issues
Abortion and reproductive health care access
Maternal Mental Health
Into the Light for Maternal Mental Health and Substance Use Disorders Act (S. 3824/H.R. 7073)
TRIUMPH for New Moms Act of 2021 (H.R. 4217/S. 2779)
Unwinding of the COVID-19 Public Health Emergency
Initiatives related to inclusion of pregnant and lactating individuals in clinical research
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) White House Office
Lobbying Issues
Permanent and mandatory extension of Medicaid for benefits for 12-months post-partum
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2022
ARTEMIS POLICY GROUP LLC filed a lobbying registration on July 20, 2022 to represent American College of Obstetricians and Gynecologists, effective May 1, 2022.
Original Filing: 301395007.xml
Issue(s) they said they’d lobby about: Abortion and reproductive health care access
Maternal Mental Health
Into the Light for Maternal Mental Health and Substance Use Disorders Act (S. 3824/H.R. 7073)
TRIUMPH for New Moms Act of 2021 (H.R. 4217/S. 2779)
Unwinding of the COVID-19 Public Health Emergency
Initiatives related to inclusion of pregnant and lactating individuals in clinical research
Permanent and mandatory extension of Medicaid for benefits for 12-months post-partum .
2nd Quarter, 2022
In Q2, ARTEMIS POLICY GROUP LLC lobbied for American College of Obstetricians and Gynecologists , earning $10,000. The report was filed on July 20, 2022.
Original Filing: 301395115.xml
Lobbying Issues
Abortion and reproductive health care access
Maternal Mental Health
Into the Light for Maternal Mental Health and Substance Use Disorders Act (S. 3824/H.R. 7073)
TRIUMPH for New Moms Act of 2021 (H.R. 4217/S. 2779)
Unwinding of the COVID-19 Public Health Emergency
Initiatives related to inclusion of pregnant and lactating individuals in clinical research
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) White House Office
Lobbying Issues
Permanent and mandatory extension of Medicaid for benefits for 12-months post-partum
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2022
In Q2, ARTEMIS POLICY GROUP LLC lobbied for The Hemophilia Alliance , earning $42,000. The report was filed on July 20, 2022.
Original Filing: 301394640.xml
Lobbying Issues
Issues related to reimbursement for hemophilia services and treatments in Medicare
Issues related to reimbursement for hemophilia services and treatments in Medicaid
Implementation of the Hemophilia SNF Access Act
CMS-1765-P; Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) U.S. Senate U.S. House of Representatives
Lobbying Issues
Funding for federal hemophilia programs
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Affordable Care Act implementation
Coverage of hemophilia treatments and services in private insurance plans, including alternative funding model
The HELP Copays Act (HR 5801)
The Protect 340B Act (HR 4390)
Private insurance policies that discriminate coverage for high cost drugs and use of patient assistance programs, also known as the (Alternative Payment Model)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Issues related to participation in the 340B Drug Discount Program
Comments to the FTC on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers (FTC-2022-0015)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Health Resources & Services Administration (HRSA) Federal Trade Commission (FTC)
1st Quarter, 2022
In Q1, ARTEMIS POLICY GROUP LLC lobbied for The Hemophilia Alliance , earning $42,000. The report was filed on April 20, 2022.
Original Filing: 301371496.xml
Lobbying Issues
Issues related to reimbursement for hemophilia services and treatments in Medicare
Issues related to reimbursement for hemophilia services and treatments in Medicaid
Implementation of the Hemophilia SNF Access Act
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) U.S. Senate U.S. House of Representatives
Lobbying Issues
Funding for federal hemophilia programs
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Affordable Care Act implementation
Coverage of hemophilia treatments and services in private insurance plans, including alternative funding model
The HELP Copays Act (HR 5801)
The Protect 340B Act (HR 4390)
Private insurance policies that discriminate coverage for high cost drugs and use of patient assistance programs, also known as the (Alternative Payment Model)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Issues related to participation in the 340B Drug Discount Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Health Resources & Services Administration (HRSA)
4th Quarter, 2021
In Q4, ARTEMIS POLICY GROUP LLC lobbied for The Hemophilia Alliance , earning $42,000. The report was filed on Jan. 20, 2022.
Original Filing: 301332827.xml
Lobbying Issues
Issues related to reimbursement for hemophilia services and treatments in Medicare
Issues related to reimbursement for hemophilia services and treatments in Medicaid
Implementation of the Hemophilia SNF Access Act
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) U.S. Senate U.S. House of Representatives
Lobbying Issues
Funding for federal hemophilia programs
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Affordable Care Act implementation
Coverage of hemophilia treatments and services in private insurance plans, including alternative funding model
The HELP Copays Act (HR 5801)
The Protect 340B Act (HR 4390)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Issues related to participation in the 340B Drug Discount Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Health Resources & Services Administration (HRSA)
3rd Quarter, 2021
In Q3, ARTEMIS POLICY GROUP LLC lobbied for The Hemophilia Alliance , earning $42,000. The report was filed on Oct. 20, 2021.
Original Filing: 301308502.xml
Lobbying Issues
Issues related to reimbursement for hemophilia services and treatments in Medicare
Issues related to reimbursement for hemophilia services and treatments in Medicaid
Implementation of the Hemophilia SNF Access Act
HR 3, Elijah E. Cummings Lower Drug Costs Now Act
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) U.S. Senate U.S. House of Representatives
Lobbying Issues
Funding for federal hemophilia programs
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Affordable Care Act implementation
Coverage of hemophilia treatments and services in private insurance plans, including alternative funding model
Accumulator adjustor issues
Protect 340B Act (HR 4390)
HHS Request for Information Regarding Reporting on Pharmacy Benefits and Prescription Drug Costs
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Issues related to participation in the 340B Drug Discount Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Health Resources & Services Administration (HRSA)
2nd Quarter, 2021
In Q2, ARTEMIS POLICY GROUP LLC lobbied for The Hemophilia Alliance , earning $42,000. The report was filed on July 20, 2021.
Original Filing: 301287041.xml
Lobbying Issues
Issues related to reimbursement for hemophilia services and treatments in Medicare
Issues related to reimbursement for hemophilia services and treatments in Medicaid
Implementation of the Hemophilia SNF Access Act
HR 3, Elijah E. Cummings Lower Drug Costs Now Act
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) U.S. Senate U.S. House of Representatives
Lobbying Issues
Funding for federal hemophilia programs
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Affordable Care Act implementation
Coverage of hemophilia treatments and services in private insurance plans, including alternative funding model
Accumulator adjustor issues
NCATS RFI on Facilitating the Early Diagnosis and Equitable Delivery of Gene-Targeted Therapies to Individuals with Rare Diseases
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Issues related to participation in the 340B Drug Discount Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Health Resources & Services Administration (HRSA)
1st Quarter, 2021
In Q1, ARTEMIS POLICY GROUP LLC lobbied for The Hemophilia Alliance , earning $42,000. The report was filed on April 19, 2021.
Original Filing: 301258227.xml
Lobbying Issues
Issues related to reimbursement for hemophilia services and treatments in Medicare
Issues related to reimbursement for hemophilia services and treatments in Medicaid
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Funding for federal hemophilia programs
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Affordable Care Act implementation
Coverage of hemophilia treatments and services in private insurance plans
Accumulator adjustor issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to participation in the 340B Drug Discount Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Health Resources & Services Administration (HRSA)
4th Quarter, 2020
In Q4, ARTEMIS POLICY GROUP LLC lobbied for The Hemophilia Alliance , earning $42,000. The report was filed on Jan. 20, 2021.
Original Filing: 301241223.xml
Lobbying Issues
Issues related to reimbursement for hemophilia services and treatments in Medicare
Issues related to reimbursement for hemophilia services and treatments in Medicaid
Coverage for telemedicine in Medicare
Hemophilia SNF Access Act (S. 3233 / H.R. 5952)
HR 133, Consolidated Omnibus Appropriations Act
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Funding for federal hemophilia programs
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Affordable Care Act implementation
Coverage of hemophilia treatments and services in private insurance plans
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to participation in the 340B Drug Discount Program
Congressional RFI regarding the 340B Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Health Resources & Services Administration (HRSA)
3rd Quarter, 2020
In Q3, ARTEMIS POLICY GROUP LLC lobbied for The Hemophilia Alliance , earning $42,000. The report was filed on Oct. 20, 2020.
Original Filing: 301219182.xml
Lobbying Issues
Issues related to reimbursement for hemophilia services and treatments in Medicare
Issues related to reimbursement for hemophilia services and treatments in Medicaid
Coverage for telemedicine in Medicare
Hemophilia SNF Access Act (S. 3233 / H.R. 5952)
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Funding for federal hemophilia programs
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Affordable Care Act implementation
Coverage of hemophilia treatments and services in private insurance plans
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to participation in the 340B Drug Discount Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Health Resources & Services Administration (HRSA)
2nd Quarter, 2020
In Q2, ARTEMIS POLICY GROUP LLC lobbied for The Hemophilia Alliance , earning $42,000. The report was filed on July 20, 2020.
Original Filing: 301198908.xml
Lobbying Issues
Issues related to reimbursement for hemophilia services and treatments in Medicare
Issues related to reimbursement for hemophilia services and treatments in Medicaid
Coverage for telemedicine in Medicare
Hemophilia SNF Access Act (S. 3233 / H.R. 5952)
Medicare interim final rule related to COVID emergency
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Funding for federal hemophilia programs
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Affordable Care Act implementation
Coverage of hemophilia treatments and services in private insurance plans
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to participation in the 340B Drug Discount Program
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Health Resources & Services Administration (HRSA)
2nd Quarter, 2020
ARTEMIS POLICY GROUP LLC filed a lobbying registration on May 12, 2020 to represent The Hemophilia Alliance, effective April 1, 2020.
Original Filing: 301182889.xml
Issue(s) they said they’d lobby about: Issues related to reimbursement for hemophilia services and treatments.
Medicare Part B Drug Reimbursement
Drug Pricing Issues
Medicare Reimbursement of SNF Services
S.2543, Prescription Drug Price Relief Act HR. 3 Lower Drug Costs Now Act of 2019 .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate